Abstracts tagged "mTor and systemic lupus erythematosus (SLE)"

Abstract Number: 2698 • 2017 ACR/ARHP Annual Meeting
IL-21-mTOR Axis Blocks the Differentiation and Function of SLE Tregs Via Suppression of Autophagy
Hiroshi Kato¹ and Andras Perl², ¹Division of Rheumatology/Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ²Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Mechanistic target of rapamycin (mTOR) activation has emerged as a prominent mediator of pro-inflammatory T-cell expansion and regulatory T (Treg) cell depletion in systemic…
Abstract Number: 2763 • 2017 ACR/ARHP Annual Meeting
mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE
Thomas Winans¹, Ryan Kelly², Zhi-Wei Lai³, Stephen Faraone², Paul E. Phillips⁴, Katalin Banki⁵ and Andras Perl³, ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Medicine, SUNY Upstate Medical University, Syracuse, NY, ⁴Dept of Medicine/Div of Rheum, SUNY-Upstate Medical Univ, Syracuse, NY, ⁵Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Anti-phospholipid antibodies (aPL) constitute a diagnostic criterion and source of morbidity, termed anti-phospholipid syndrome (APS), in patients with or without systemic lupus erythematosus (SLE).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].